BPN-14770
This note is educational and is not personal medical advice. Effects vary by baseline status, dose, product quality, medications, sleep debt, diet, and health conditions.
Summary / What it does
BPN-14770 is a selective inhibitor of phosphodiesterase 4D (PDE4D) — an enzyme that breaks down cyclic AMP (cAMP). By preventing cAMP degradation, it activates CREB signaling and downstream BDNF/NGF production, enhancing synaptic plasticity and memory consolidation. It is currently in clinical trials for Alzheimer’s disease and Fragile X Syndrome.
Useful cross-links: Neurotrophic & Growth Factors, Dopamine Modulation, Neurotransmitter Balance. Its effects are best evaluated through the Acute & Instant Effects pattern rather than as a single isolated effect.
How it works in the brain (detailed scientific mechanisms)
Phosphodiesterase 4D (PDE4D) is the primary cAMP-metabolizing enzyme in the hippocampus and prefrontal cortex. cAMP is a second-messenger critical to the PKA → CREB → BDNF transcription axis, which underlies LTP and long-term memory consolidation. By selectively inhibiting PDE4D, BPN-14770 elevates cAMP in memory-critical circuits, activating this plasticity cascade without the widespread PDE4 inhibition that causes emetic side effects with older nonselective PDE4 inhibitors like rolipram.
The PDE4D subtype selectivity is key to BPN-14770’s differentiation from earlier compounds. Emesis and nausea from PDE4 inhibition are primarily mediated by PDE4D in the area postrema; BPN-14770’s partial inhibition profile appears to maintain cognitive cAMP benefits while partially sparing the emetic pathway. This compound also influences dopamine signaling indirectly — cAMP is a major downstream effector of D1 receptor activation in prefrontal circuits, linking BPN-14770 to working memory and executive function.
Related mechanism notes: Neurotrophic & Growth Factors, Dopamine Modulation, Neurotransmitter Balance.
Different variations/forms
Oral capsule formulation used in clinical trials. No retail supplement form exists.
Time to action / onset
Based on cAMP-CREB signaling kinetics, meaningful memory consolidation effects would likely require hours to emerge acutely and possibly days to weeks for full neurotrophic benefit.
Half-life
Not publicly established from completed clinical pharmacokinetic studies.
Dosage
Phase 1 trials have established preliminary tolerability at low single-digit milligram doses. No consumer dose can be recommended — this is a clinical investigational compound.
Positive effects
Theoretical positive effects based on mechanism and preclinical data include enhanced memory consolidation, long-term potentiation support, BDNF upregulation, and improved working memory through cAMP-D1 signaling.
Reported Effects
No established human anecdotal experience profile. Animal models of Fragile X and Alzheimer’s show significant improvements in learning tasks, hyperactivity, and fear extinction.
Side effects / contraindications
Known PDE4 class side effects include nausea and emesis, which BPN-14770’s subtype selectivity is designed to reduce but not eliminate. No long-term human safety data exists. Not for self-administration.
Where it is found in food or nature (natural sources)
BPN-14770 is fully synthetic with no natural food sources.
Protocol
No protocol can be responsibly recommended. BPN-14770 is an investigational new drug in active clinical trials and has no established consumer dosing or safety profile. Do not self-administer.
Key Research
- Bhatt et al. (2020): Phase 1 trial of BPN-14770 in healthy volunteers confirmed tolerability, favorable PK profile, and early evidence of cognitive signal.
- Gurney et al. (2011): Preclinical work establishing PDE4D subtype selectivity and cognitive enhancement in rodent fear conditioning and spatial memory models.
- Silverman et al. (2020): Clinical trial in Fragile X Syndrome found BPN-14770 improved cognitive and behavioral outcomes compared to placebo, supporting clinical development.
Forms & Sourcing
Investigational drug — available only through clinical trial participation at designated research sites. Not commercially available as a supplement.
Other notes
BPN-14770 represents the most advanced clinical-stage novel cognitive enhancer in this section of the wiki. Its cAMP-CREB-BDNF mechanism connects it strongly to Neurotrophic & Growth Factors alongside NSI-189, Semax, and Lions Mane. Its dopamine-adjacent cAMP mechanism also connects to Dopamine Modulation.
Related notes: ACD-856, Neboglamine, NSI-189, Semax, Neurotrophic & Growth Factors